knowledge -WSS

knowledge

author：leisure time 2025-10-01 20:16:00 - browse：16

WASHINGTON, DC - NOVEMBER 27: U.S. President Joe Biden speaks about supply chain resilience during an event in the Indian Treaty Room at the Eisenhower Executive Office Building on November 27, 2023 in Washington, DC. — President Biden spoke about supply chain resilience and drug shortages. Alex Wong/Getty Images

WASHINGTON — President Biden’s new plan to curb drug shortages by boosting domestic drug production won’t expand the supply of the chemotherapies that are currently in shortage, an administration official confirmed. The limited scope surprised experts, who told STAT Biden could have included those drugs in the effort.

The 15 cancer drugs in short supply account for only a little more than 10% of the drugs on FDA’s shortage list. But chemotherapies are far more crucial than many other drugs experiencing shortages, which include injections of amino acids and multivitamins, and sterile water. Gut-wrenching stories about cancer patients being switched to less-effective drugs have caused cancer doctors to agitate for government solutions.

Biden announced last week that he plans to use the Defense Production Act to get companies to make essential medicines and their ingredients in the United States. The administration will spend $35 million to boost domestic production of key starting materials for drugs that hospitals commonly use and are prone to shortages.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Vertex non

hotspot

WSS

Health Care Service Corp to buy Cigna Medicare Advantage plans

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Investment in vaccine development is lagging, report finds

Mirador, a new biotech startup, launches with $400 million

Yancopoulos of Regeneron works to expand Dupixent success

hotspot

knowledge

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Pregnancy ages women, but effects reverse after delivery

Affirmative action in medical school literally saved lives

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Moonlake's readout produced a cash windfall. Risks remain

Reconstructing family trees of blood cells may help predict disease

Medicare proposal to cover medical devices draws a mixed reaction

Why you shouldn’t ask, “What country has the best health care?”

Supreme Court strikes down use of affirmative action

New clues to why women have higher risk of autoimmune disorders

focus

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Cancer, immunology, HIV research ensnared in fetal tissue politics

Adam's Take: Intra

Merck CEO won’t testify in Senate, citing no expertise in drug prices

U.K. officials, researchers try to ease path for bespoke genetic treatments

Cancer, immunology, HIV research ensnared in fetal tissue politics

hotspot

leisure time

focus

knowledge